Search

everythinglearnresearchcommunity

for

Search:↓

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Sorafenib may cause hair loss in a way similar to alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

ATP helps prevent skin damage from vandetanib by reducing stress.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Minoxidil might partially activate estrogen receptors, affecting hair growth.

Two new compounds were found that could promote hair growth as well or better than minoxidil.

mTORC2 is crucial for healthy skin barrier by regulating lipids and filaggrin.

AL136131.3 slows hair growth by affecting energy processes in hair loss.

Antisense oligonucleotides can reduce androgen receptor levels in skin cells, suggesting potential for treating skin disorders.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Scientists created tiny particles loaded with a hair growth drug, minoxidil, that specifically target hair follicles and skin cells to potentially improve hair growth.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

mTORC1 activity is important for hair growth and color, and targeting it could help treat hair loss and greying.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

JAK inhibitors may soon be a safe and effective treatment for alopecia areata.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.

Verteporfin reduces growth and stem cell traits in rat hair follicle cells by blocking the Hippo pathway.